Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Average PT from Analysts

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been assigned an average rating of “Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.50.

A number of analysts have commented on IPSC shares. Piper Sandler lowered their price target on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research report on Monday, December 30th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Guggenheim restated a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd.

Century Therapeutics Trading Down 0.9 %

NASDAQ:IPSC opened at $0.58 on Thursday. Century Therapeutics has a 12 month low of $0.55 and a 12 month high of $5.24. The firm has a fifty day simple moving average of $0.76 and a 200-day simple moving average of $1.17. The company has a market capitalization of $49.57 million, a P/E ratio of -0.32 and a beta of 1.75.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IPSC. Marshall Wace LLP acquired a new position in Century Therapeutics in the fourth quarter valued at approximately $36,000. Jane Street Group LLC lifted its stake in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Century Therapeutics in the 4th quarter valued at $52,000. Sei Investments Co. acquired a new position in shares of Century Therapeutics in the fourth quarter worth about $53,000. Finally, Two Sigma Investments LP acquired a new position in shares of Century Therapeutics in the fourth quarter worth about $67,000. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.